Comparison · NCT05780437-deaths
AZD7442 Plus SOC vs Placebo Plus SOC: deaths from any cause
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. AZD7442 Plus SOC vs Placebo Plus SOC: deaths from any cause. Trial comparisons, record NCT05780437-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT05780437-deaths
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0859 | 0.0675 | 0.109 | wilson | |
| Risk in group 2 | 0.122 | 0.0996 | 0.148 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0357 | -0.0677 | -0.00392 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.706 | 0.517 | 0.964 | log | |
| Odds ratio, group 1 over group 2 | 0.679 | 0.48 | 0.959 | log | |
| Number needed to treat, for one fewer death from any cause on AZD7442 Plus SOC than on Placebo Plus SOC | 28 | 14.8 | 255 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | AZD7442 Plus SOC | * AZD7442 600 mg solution (separate vials containing 300 mg each of AZD88995 and AZD1061); administered by IV infusion~* Remdesivir is provided to all study participants as SOC unless contraindicated for an individual patient; administered by IV infusion~AZD7442: AZD8895 and AZD1061, known collectively as AZD7442, are two fully human neutralizing immunoglobulin G (IgG)-1 kappa monoclonal antibodies (mAb) that target two distinct epitopes on the receptor-binding domain of the spike protein of SARS-CoV- 2.~Remdesivir: Antiviral agent | 61 | 710 | EG000 |
| Group 2 | Placebo Plus SOC | * Placebo administered by IV infusion~* Remdesivir is provided to all study participants as SOC unless contraindicated for an individual patient; administered by IV infusion~Placebo: Commercially available 0.9% sodium chloride solution~Remdesivir: Antiviral agent | 86 | 707 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, all-cause mortality
- Time frame
- 90 Days
Source ClinicalTrials.gov
Trial
- Title
- AZD7442 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)
- NCT number
- NCT05780437
- Phases
- PHASE3
- Conditions
- COVID-19
- Interventions
- AZD7442, Placebo, Remdesivir
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Results first posted
- 2024-07-30
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT05780437?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT05780437-deaths